Intellect Neurosciences, Inc. CEO Granted New Patent by European Patent and Trademark Office Related to Potential Treatment for Memory Loss and Dementia
August 11, 2010 07:53 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Aug. 11, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major...
Intellect Neurosciences, Inc. Receives U.S. Patent Allowance for Alzheimer's Vaccine With Potential to Delay Onset or Prevent Alzheimer's Disease
August 10, 2010 08:47 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Aug. 10, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc (OTCBB:ILNS) a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major...
Intellect Neurosciences, Inc. Receives Notice of Allowance for Patent on Alzheimer's Drug From the Canadian Patent and Trademark Office
August 09, 2010 08:00 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Aug. 9, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc (OTCBB:ILNS) announced that it has received a Notice of Allowance from the Canadian Patent and Trademark Office for a new patent...
Intellect Neurosciences, Inc. Encouraged by Clinical Trial Data in Relation to Its Alzheimer's Immunotherapy Patents and Technology
July 15, 2010 08:00 ET
|
Intellect Neurosciences, Inc.
NEW YORK, July 15, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
Intellect Neurosciences, Inc. Applauds Recent Media Coverage
July 14, 2010 07:30 ET
|
Intellect Neurosciences, Inc.
NEW YORK, July 14, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
Intellect Neurosciences, Inc. to Present at OneMedForum New York 2010 Emerging Company Finance Conference
June 28, 2010 07:30 ET
|
Intellect Neurosciences, Inc.
NEW YORK, June 28, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
Intellect Neurosciences, Inc. Receives Notice of Allowance for Patent on Alzheimer's Drug From the Israeli Patent and Trademark Office
June 09, 2010 07:30 ET
|
Intellect Neurosciences, Inc.
NEW YORK, June 9, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc (OTCBB:ILNS) announced it has received a Notice of Allowance from the Israeli Patent and Trademark Office for a new patent...
Intellect Neurosciences, Inc. Receives Notice of Allowance for Alzheimer Monoclonal Antibody Patent from the United States Patent and Trademark Office
June 03, 2010 08:00 ET
|
Intellect Neurosciences, Inc.
NEW YORK, June 3, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office...
Intellect Neurosciences and CARBOGEN AMCIS Reach Debt Settlement Agreement
May 06, 2010 07:54 ET
|
Intellect Neurosciences, Inc.
NEW YORK, May 6, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease...
Intellect Neurosciences, Inc. Restructures Balance Sheet
April 26, 2010 08:00 ET
|
Intellect Neurosciences, Inc.
NEW YORK, April 26, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's...